Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has terminated its share purchase agreement with Triton Funds LP, which afforded Triton the opportunity to purchase up to 18.8% of the Company's common stock..

马萨诸塞州马尔伯勒--（新闻文件公司-2024年7月5日）-Phio Pharmaceuticals Corp.（纳斯达克：Phio），一家临床阶段生物技术公司，其专有的INTASYL®siRNA基因沉默技术旨在使免疫细胞更有效地杀死肿瘤细胞，今天宣布终止与Triton Funds LP的股份购买协议，这使Triton有机会购买公司高达18.8%的普通股。。

About Phio Pharmaceuticals Corp.

关于Phio Pharmaceuticals Corp。

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics.

Phio Pharmaceuticals Corp.（纳斯达克：Phio）是一家临床阶段生物技术公司，其专有的INTASYL®siRNA基因沉默技术旨在使免疫细胞更有效地杀死肿瘤细胞。INTASYL是唯一专注于免疫肿瘤学治疗的自我递送RNAi技术。

INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems..

INTASYL药物精确地靶向特定的蛋白质，这些蛋白质会降低身体对抗癌症的能力，而不需要专门的配方或药物输送系统。。

For additional information, visit the Company's website, www.phiopharma.com.

有关更多信息，请访问该公司的网站www.phiopharma.com。

Contact:

联系人：

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp。

ir@phiopharma.com

ir@phiopharma.com

PR Contact

公关联系人

Michael Adams

迈克尔·亚当斯

Bridge View Media

Bridge View媒体

adams@bridgeviewmedia.com

adams@bridgeviewmedia.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/215358

要查看此新闻稿的源版本，请访问https://www.newsfilecorp.com/release/215358